Shang Y, Yan CY, Li H, Liu N, Zhang HF. Tiliroside protects against diabetic nephropathy in streptozotocin-induced diabetes rats by attenuating oxidative stress and inflammation. World J Diabetes 2024; 15(11): 2220-2236 [DOI: 10.4239/wjd.v15.i11.2220]
Corresponding Author of This Article
Hui-Feng Zhang, MM, Doctor, Department of Nephrology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, No. 99 Longcheng Street, Xiaodian District, Taiyuan 030032, Shanxi Province, China. zhanghuifeng1977@163.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Nov 15, 2024; 15(11): 2220-2236 Published online Nov 15, 2024. doi: 10.4239/wjd.v15.i11.2220
Tiliroside protects against diabetic nephropathy in streptozotocin-induced diabetes rats by attenuating oxidative stress and inflammation
Yan Shang, Cai-Yun Yan, Hui Li, Na Liu, Hui-Feng Zhang
Yan Shang, Cai-Yun Yan, Hui Li, Na Liu, Hui-Feng Zhang, Department of Nephrology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan 030032, Shanxi Province, China
Author contributions: Shang Y and Yan CY designed the research study; Shang Y, Li H, and Liu N performed the research; Yan CY and Zhang HF contributed new reagents and analytic tools; Shang Y, Li H, and Zhang HF analyzed the data and wrote the manuscript. All authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the Ethical Committee of Shanxi Bethune Hospital (Approval No. YXLL-2023-222).
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of Shanxi Province Hospital of Traditional Chinese medicine (Approval No. AWE202209013).
Conflict-of-interest statement: All authors declare that they have no competing interests to disclose.
Data sharing statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui-Feng Zhang, MM, Doctor, Department of Nephrology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, No. 99 Longcheng Street, Xiaodian District, Taiyuan 030032, Shanxi Province, China. zhanghuifeng1977@163.com
Received: April 2, 2024 Revised: August 17, 2024 Accepted: September 23, 2024 Published online: November 15, 2024 Processing time: 197 Days and 3.8 Hours
Abstract
BACKGROUND
Diabetic nephropathy (DN), affecting half of diabetic patients and contributing significantly to end-stage kidney disease, poses a substantial medical challenge requiring dialysis or transplantation. The nuanced onset and clinical progression of kidney disease in diabetes involve consistent renal function decline and persistent albuminuria.
AIM
To investigate Tiliroside's (Til) protective effect against diabetic nephropathy (DN) in rats under diabetic conditions.
METHODS
Five groups of six rats each were included in this study: Rats treated with DMSO by intraperitoneal injection as controls, those treated with STZ by intraperitoneal injection, those treated with STZ + Til (25 mg/kg body weight [bwt]) or Til (50 mg/kg bwt), and those treated with anti-diabetic medication glibenclamide (600 μg/kg bwt). Biochemical markers, fasting blood glucose, food intake, kidney weight, antioxidant enzymes, inflammatory and fibrotic markers, and renal injury were monitored in different groups. Molecular docking analysis was performed to identify the interactions between Til and its targeted biomarkers.
RESULTS
Til significantly reduced biochemical markers, fasting blood glucose, food intake, and kidney weight and elevated antioxidant enzymes in diabetic rats. It also mitigated inflammatory and fibrotic markers, lessened renal injury, and displayed inhibitory potential against crucial markers associated with DN as demonstrated by molecular docking analysis.
CONCLUSION
These findings suggest Til's potential as a therapeutic agent for DN treatment, highlighting its promise for future drug development.
Core Tip: Tiliroside (Til) demonstrates potent protective effects against diabetic nephropathy (DN) in rats, alongside glibenclamide. Through attenuating oxidative stress, inflammation, and fibrosis, Til treatment significantly improves renal function and reduces biochemical markers associated with DN. Molecular docking analysis reveals its potential inhibition of key markers linked to the disease. These findings underscore Til's promising role as a therapeutic agent for DN, suggesting avenues for future drug development.
